TherapeuticsMD (TXMD) vs. Its Peers Head to Head Survey

TherapeuticsMD (NASDAQ:TXMD) is one of 897 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare TherapeuticsMD to related businesses based on the strength of its profitability, institutional ownership, analyst recommendations, dividends, valuation, risk and earnings.

Profitability

This table compares TherapeuticsMD and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	-6.64%	-1.09%	-0.78%
TherapeuticsMD Competitors	-2,380.91%	-221.72%	-15.99%

Analyst Recommendations

This is a breakdown of current ratings and price targets for TherapeuticsMD and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1	0	0	0	1.00
TherapeuticsMD Competitors	7765	13847	25696	1031	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 23.99%. Given TherapeuticsMD’s peers stronger consensus rating and higher possible upside, analysts plainly believe TherapeuticsMD has less favorable growth aspects than its peers.

Insider & Institutional Ownership

30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 32.4% of shares of all “Pharmaceuticals” companies are held by institutional investors. 1.7% of TherapeuticsMD shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

TherapeuticsMD has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, TherapeuticsMD’s peers have a beta of -4.30, suggesting that their average share price is 530% less volatile than the S&P 500.

Earnings and Valuation

This table compares TherapeuticsMD and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
TherapeuticsMD	$3.02 million	-$570,000.00	90.00
TherapeuticsMD Competitors	$3.54 billion	$3.17 billion	546.63

TherapeuticsMD’s peers have higher revenue and earnings than TherapeuticsMD. TherapeuticsMD is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

TherapeuticsMD peers beat TherapeuticsMD on 9 of the 13 factors compared.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.